• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xoma Royalty Corporation (NQ: XOMA )

    31.10 +0.24 (+0.78%)
    Streaming Delayed Price Updated: 3:39 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,899
    Open 30.42
    Bid (Size) 30.77 (1)
    Ask (Size) 31.03 (1)
    Prev. Close 30.86
    Today's Range 30.22 - 31.49
    52wk Range 14.27 - 31.93
    Shares Outstanding 11,704,467
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
    From XOMA Corporation
    Via GlobeNewswire
    Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
    From XOMA Corporation
    Via GlobeNewswire

    Performance

    YTD
    +48.88%
    +48.88%
    1 Month
    +13.46%
    +13.46%
    3 Month
    +32.12%
    +32.12%
    6 Month
    +24.30%
    +24.30%
    1 Year
    +78.94%
    +78.94%

    More News

    Read More
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    Demystifying XOMA: Insights From 5 Analyst Reviews
    Via Benzinga
    Peeling Back The Layers: Exploring XOMA Through Analyst Insights
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For XOMA
    Via Benzinga
    XOMA Royalty to Present at Upcoming Investor Conferences in September
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
    Via Benzinga
    Exposures Product Safety
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
    From XOMA Corporation
    Via GlobeNewswire
    3 Crazy Good Stocks to Buy With $500 Right Now
    Via InvestorPlace
    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Corporation Announces Closing of Tender Offer
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.